Usefulness of a novel and rapid assay system for fecal calprotectin in pediatric patients with inflammatory bowel diseases

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 7, 2014, Pages 1406-1412

  Inoue, Keisuke ^a   Aomatsu, Tomoki ^a   Yoden, Atsushi ^a   Okuhira, Takeru ^a   Kaji, Emiri ^a   Tamai, Hiroshi ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Biomarker; Children; Fecal calprotectin; Inflammatory bowel disease

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; FECAL CALPROTECTIN; HEMOGLOBIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; COLLOIDAL GOLD;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; COLLOIDAL GOLD AGGREGATION ASSAY; CONTROLLED STUDY; CROHN DISEASE; ENDOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; EVALUATION STUDY; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOCHEMISTRY; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; CHEMISTRY; DIAGNOSTIC USE; FECES; INFANT; INFLAMMATORY BOWEL DISEASES; PRESCHOOL CHILD; PROCEDURES;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; FECES; FEMALE; GOLD COLLOID; HUMANS; IMMUNOCHEMISTRY; INFANT; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; SENSITIVITY AND SPECIFICITY;

EID: 84904351612     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12578     Document Type: Article

References (43)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434.
2. Pigneur B, Seksik P, Viola S etal. Natural history of Crohn's disease: comparison between childhood- and adult-onset disease. Inflamm. Bowel Dis. 2010; 16: 953-961.
3. Ishige T, Tomomasa T, Takebayashi T etal. Inflammatory bowel disease in children: epidemiological analysis of the nationwide IBD registry in Japan. J. Gastroenterol. 2010; 45: 911-917.
4. Froslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-422.
5. Schnitzler F, Fidder H, Ferrante M etal. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm. Bowel Dis. 2009; 15: 1295-1301.
6. van Beek EJ, Leroy PL. Safe and effective procedural sedation for gastrointestinal endoscopy in children. J. Pediatr. Gastroenterol. Nutr. 2012; 54: 171-185.
7. Goyette J, Geczy CL. Inflammation-associated S100 proteins: new mechanisms that regulate function. Amino Acids 2011; 41: 821-842.
8. Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am. J. Gastroenterol. 2013; DOI: 10.1038/ajg.2013.131.
9. Costa F, Mumolo MG, Bellini M etal. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig. Liver Dis. 2003; 35: 642-647.
10. Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997; 58: 176-180.
11. Limburg PJ, Ahlquist DA, Sandborn WJ etal. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am. J. Gastroenterol. 2000; 95: 2831-2837.
12. Hanai H, Takeuchi K, Iida T etal. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig. Dis. Sci. 2004; 49: 1438-1443.
13. Gaya DR, Lyon TD, Duncan A etal. Faecal calprotectin in the assessment of Crohn's disease activity. QJM 2005; 98: 435-441.
14. Sipponen T, Karkkainen P, Savilahti E etal. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment. Pharmacol. Ther. 2008; 28: 1221-1229.
15. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm. Bowel Dis. 2009; 15: 1851-1858.
16. Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2001; 32: 171-177.
17. Fagerberg UL, Loof L, Lindholm J, Hansson LO, Finkel Y. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2007; 45: 414-420.
18. Quail MA, Russell RK, Van Limbergen JE etal. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease. Inflamm. Bowel Dis. 2009; 15: 756-759.
19. Aomatsu T, Yoden A, Matsumoto K etal. Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig. Dis. Sci. 2011; 56: 2372-2377.
20. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369.
21. Tanaka M, Matsuo K, Enomoto M, Mizuno K. A sol particle homogeneous immunoassay for measuring serum cystatin C. Clin. Biochem. 2004; 37: 27-35.
22. Kawakita M, Hiramatsu K, Yanagiya M, Doi Y, Kosaka M. Determination of N(1), N(1)(2)-diacetylspermine in urine: a novel tumor marker. Methods Mol. Biol. 2011; 720: 367-378.
23. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J. Pediatr. Gastroenterol. Nutr. 2005; 41: 1-7.
24. Turner D, Otley AR, Mack D etal. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007; 133: 423-432.
25. Hyams JS, Ferry GD, Mandel FS etal. Development and validation of a pediatric Crohn's disease activity index. J. Pediatr. Gastroenterol. Nutr. 1991; 12: 439-447.
26. Levine A, Griffiths A, Markowitz J etal. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm. Bowel Dis. 2011; 17: 1314-1321.
27. De Roe C, Courtoy PJ, Baudhuin P. A model of protein-colloidal gold interactions. J. Histochem. Cytochem. 1987; 35: 1191-1198.
28. Aomatsu T, Imaeda H, Matsumoto K etal. Faecal chitinase 3-like-1: a novel biomarker of disease activity in paediatric inflammatory bowel disease. Aliment. Pharmacol. Ther. 2011; 34: 941-948.
29. Matts SG. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q. J. Med. 1961; 30: 393-407.
30. Daperno M, D'Haens G, Van Assche G etal. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest. Endosc. 2004; 60: 505-512.
31. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand. J. Gastroenterol. 1992; 27: 793-798.
32. Ton H, Brandsnes OE, Dale S etal. Improved assay for fecal calprotectin. Clin. Chim. Acta 2000; 292: 41-54.
33. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am. J. Gastroenterol. 2008; 103: 162-169.
34. Schoepfer AM, Beglinger C, Straumann A etal. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm. Bowel Dis. 2013; 19: 332-341.
35. Schoepfer AM, Beglinger C, Straumann A etal. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am. J. Gastroenterol. 2010; 105: 162-169.
36. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm. Bowel Dis. 2008; 14: 40-46.
37. Sipponen T, Savilahti E, Karkkainen P etal. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm. Bowel Dis. 2008; 14: 1392-1398.
38. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 2004; 39: 1017-1020.
39. Allison JE. Review article: faecal occult blood testing for colorectal cancer. Aliment. Pharmacol. Ther. 1998; 12: 1-10.
40. Nakarai A, Kato J, Hiraoka S etal. Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test. Am. J. Gastroenterol. 2013; 108: 83-89.
41. Guittet L, Guillaume E, Levillain R etal. Analytical comparison of three quantitative immunochemical fecal occult blood tests for colorectal cancer screening. Cancer Epidemiol. Biomarkers Prev. 2011; 20: 1492-1501.
42. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 2009; 58: 859-868.
43. Naito Y, Takagi T, Yoshikawa T. Molecular fingerprints of neutrophil-dependent oxidative stress in inflammatory bowel disease. J. Gastroenterol. 2007; 42: 787-798.